JSF Financial LLC Acquires 114 Shares of United Therapeutics Co. (NASDAQ:UTHR)

JSF Financial LLC raised its position in United Therapeutics Co. (NASDAQ:UTHR) by 4.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,996 shares of the biotechnology company’s stock after purchasing an additional 114 shares during the period. JSF Financial LLC’s holdings in United Therapeutics were worth $1,057,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics in the 4th quarter valued at about $25,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics in the third quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics in the third quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB increased its position in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of United Therapeutics in the third quarter valued at about $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the transaction, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 111,864 shares of company stock worth $41,036,365. Company insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on UTHR. Argus lifted their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. The Goldman Sachs Group lifted their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Trading Down 0.6 %

Shares of UTHR stock opened at $345.64 on Tuesday. The stock has a market cap of $15.43 billion, a P/E ratio of 15.18, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. The stock has a 50 day simple moving average of $362.37 and a 200 day simple moving average of $358.13. United Therapeutics Co. has a 1 year low of $210.64 and a 1 year high of $417.82.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.